A Randomized Double-Blind Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Allergic Rhinitis
-
Age: Between 12 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Weight must be equal to or greater than 40 kg at the time of screening
- Documented or patient reported history (for at least 2 years) of symptomatic cat allergen triggered allergic rhinitis with or without conjunctivitis and with or without asthma
- At least 1 generally healthy cat (that is unlikely to die during the study) living in the home resulting in regular exposure
- Willing and able to comply with clinic visits and study-related procedures
- Provide informed consent
- Able to understand and complete study-related questionnaires
You may not be eligible for this study if the following are true:
-
- History of significant multiple and/or severe allergies
- Received REGN1908-1909 in a prior REGN1908-1909 clinical trial
- Active lung disease other than asthma
- Treatment with an investigational drug within 2 months or within 5 half-lives
- Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections within 4 weeks prior to screening.
- Use of anti-IgE or other biological therapy (including but not limited to anti IL-5, anti IL-4) that interferes with type 2 disease within 6 months prior to screening visit 1
- Specific immunotherapy (SIT) with cat allergen or cat vaccine within 6 months prior to screening visit 1
- SIT with any allergen other than cat within 6 months prior to screening visit 1
- Patients who have recently started (within 12 weeks prior to screening visit 1) and plan to continue or plan to start their cat(s) on an anti-allergen cat food (eg, Purina Pro Plan® LiveClear) or other anti-allergen treatment during the study
- History of life-threatening asthma
- History of intensive care hospitalization for asthma within past 2 years
- History of intolerance to systemic or topical corticosteroids or antihistamines, or drug treatment excipient
- History of nasal polyps
- History of drug or alcohol abuse within a year prior to screening
- Any malignancy within the past 5 years
- Pregnant or breastfeeding women
- Women of childbearing potential (WOCBP)* who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 24 weeks after the last dose
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.